Antitumor Effect of Everolimus in a Patient with Type 3 Gastric Neuroendocrine Tumor

Publisher： Karger

E-ISSN： 2296-5262|36|9|502-504

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.36, Iss.9, 2013-08, pp. : 502-504

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and Long-Term Safety of Everolimus in Pancreatic Neuroendocrine Tumor Associated with Multiple Endocrine Neoplasia Type I: Case Report

By  

Oncology Research and Treatment, Vol. 39, Iss. 10, 2016-09 ,pp. : 643-645

Karger

Access to resources Recommend Favorite

Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases

By                      

International Journal of Molecular Medicine, Vol. 30, Iss. 1, 2012-01 ,pp. : 126-132

Spandidos Publications

Access to resources Recommend Favorite

A Case of Metastatic Gastric Neuroendocrine Tumor: Therapeutic Considerations

By  

Case Reports in Oncology, Vol. 7, Iss. 1, 2014-04 ,pp. : 266-272

Karger

Access to resources Recommend Favorite

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor

By  

Case Reports in Oncology, Vol. 8, Iss. 3, 2015-10 ,pp. : 461-465

Karger

Access to resources Recommend Favorite

Strong Anti‐tumor Effect of Monosialoganglioside Specific Monoclonal Antibody 202: A Clinical Trial in a Cancer Patient with Melanoma

By  

THE JOURNAL OF DERMATOLOGY, Vol. 16, Iss. 6, 1989-12 ,pp. : 480-486

John Wiley & Sons Inc

Access to resources Recommend Favorite